NCT01501435

To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study to Compare the Pharmacokinetics of CJ-30039 and Lipidil Supra and to Investigate Food-effect on Pharmacokinetics of CJ-30039

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: HK inno.N Corporation · Industry
• Sex: Male
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra

Detailed description

Study objectives * To compare the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra after a single oral administration in healthy male volunteers. * To evaluate the food-effect on pharmacokinetics of CJ-30039 after a single oral administration in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	CJ-30039	single dose
DRUG	fenofibric acid	single dose

Timeline

• Start date: 2011-12-01
• Primary completion: 2012-04-01
• Completion: 2012-06-01
• First posted: 2011-12-29
• Last updated: 2017-01-02

Locations

1 site across 1 country: South Korea